August 14, 2020

On Criteo

 The Fool still owns shares of Criteo, which had a decent quarter in the COVID environment. 

August 11, 2020

Update on Aimmune Therapeutics

 The Fool is out with a small update on Aimmune Therapeutics.  They do not own shares. 

July 27, 2020

July 8, 2020

5 Reasons to Own Livongo Health

The Fool has an article on 5 Reasons to Own Livongo Health. 

June 26, 2020

PING Identity

The Fool owns shares of PING, which provides a similar service to Okta.  Gartner sees them as a leader behind Microsoft and Okta. 

June 24, 2020

3 Big Data Healthcare Stocks

From the Fool:

"I believe Health Catalyst has the most growth opportunities. If you're looking for the safest bet, Cerner is an entrenched dominant player in the industry, and it even began offering a dividend last year of $0.18 per quarter. Globus Medical splits the middle, offering plenty of growth with a lower level of risk."

June 1, 2020

Roku and Livongo

The Fool is high on Roku and Livongo Health 

April 29, 2020

Why I Bought CGBD

From SA where the author bought CGBD and its 21% yield. 

March 3, 2020

Riding Peanut Allergy Treatment to Profits

Aimmune Therapeutics has the only FDA approved peanut allergy treatment on the market, which may translate into big profits for the company:

Liana Moussatos of Wedbush Securities has reiterated the firm’s Outperform rating on Aimmune. She has lowered her target price down to $66 from $74 after previously having a high of $81 for the stock. Some target price cuts are not well received, but this stock being close to $23 still represents close to 200% in implied upside.

With the PALFORZIA launch ongoing, Liana Moussatos sees the potential for Aimmune to popularize the oral immunotherapy treatment for peanut allergy in the United States. It was on January 31, 2020 that the FDA approved PALFORZIA for the reduction of allergic reactions, which included anaphylaxis, which may occur from accidental peanut exposure.

Where Wedbush sees the big growth is in revenues, effectively ramping up to a blockbuster drug category in the coming years. With expected 2020 product sales expected to be just $18.67 million, the official projections for product sales ahead are as follows:
  • $91.3 million in 2021,
  • $310.6 million in 2022,
  • $899.3 million in 2023,
  • $1.83 billion in 2024,
  • and ultimately $2.46 billion in 2025.

February 14, 2020

Alexion: An Undervalued Growth Stock

From Christina Huff:

lexion Pharmaceuticals (ALXN) is a biopharmaceutical company that researches and manufactures treatments of severe and rare health disorders; I consider this an undervalued growth stock, notes Crista Huff, editor of Cabot 
Undervalued Stocks Advisor.

The company just reported a good fourth quarter; revenue was $1.38 billion and non-GAAP EPS was $2.71, each higher than the respective consensus estimates of $1.31 billion and $2.60.

All four pharmaceutical brands — Soliris, Ultomiris, Strensiq and Kanuma — delivered higher-than-expected revenue. Full-year 2019 EPS was $10.53 vs. the expected $10.43, up 33.0% vs. the prior year. The earnings report itemizes nearly 20 projects and clinical trials that Alexion is currently pursuing.

Management expects to achieve revenue in a range of $5.50-$5.56 billion in 2020, and non-GAAP EPS in a range of $10.65-$10.85. The prior consensus 2020 revenue and EPS estimates were $5.64 billion and $11.37, respectively.
The stock fell as investors expressed their disappointment that the costs of the Achillion acquisition will impact full-year 2020 profits, as will an increased tax rate, and the higher R&D costs associated with Alexion’s current volume of clinical trials.

I keep track of earnings estimates during the entire time that I follow any particular company, and I’ve been following Alexion for many years. Its earnings estimates climb consistently throughout each year, and even at year end, the final results outperform Wall Street estimates.

Therefore, the current expectation of 3% EPS growth in 2020 is likely a very low estimate vs. the number Alexion will ultimately report a year from now. In that light, I think today’s reaction to the share price was just plain silly.

The company grew EPS 27%, 35% and 33% in 2017 through 2019. The 2020 P/E is 9.3, which is extremely low for a biopharmaceutical stock. I’m moving ALXN from "Buy" to a "Strong Buy" recommendation. The stock is cheap. Patient growth stock investors should accumulate these shares.